These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38828891)

  • 1. Electrocardiographic Findings in Children Treated with Leuprolide Acetate for Precocious Puberty: Does it Cause Prolonged QT?
    Altun EE; Yaşar A; Dursun F; Seymen G; Kırmızıbekmez H
    J Clin Res Pediatr Endocrinol; 2024 Jun; ():. PubMed ID: 38828891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the Efficacy of Treatment with a GnRH Analogue in Patients with Central Precocious Puberty.
    Kendirci HN; Ağladıoğlu SY; Baş VN; Önder A; Çetinkaya S; Aycan Z
    Int J Endocrinol; 2015; 2015():247386. PubMed ID: 26550013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty.
    Lee PA; Klein K; Mauras N; Neely EK; Bloch CA; Larsen L; Mattia-Goldberg C; Chwalisz K
    J Clin Endocrinol Metab; 2012 May; 97(5):1572-80. PubMed ID: 22344198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty.
    Clemons RD; Kappy MS; Stuart TE; Perelman AH; Hoekstra FT
    Am J Dis Child; 1993 Jun; 147(6):653-7. PubMed ID: 8506834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter clinical trial of leuprolide acetate depot (Luphere depot 3.75 mg) for efficacy and safety in girls with central precocious puberty.
    Kim YJ; Lee HS; Lee YJ; Lim JS; Kim SY; Kim EY; Jin DK; Hwang IT; Hwang JS
    Ann Pediatr Endocrinol Metab; 2013 Dec; 18(4):173-8. PubMed ID: 24904873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty.
    Klein KO; Freire A; Gryngarten MG; Kletter GB; Benson M; Miller BS; Dajani TS; Eugster EA; Mauras N
    J Clin Endocrinol Metab; 2020 Oct; 105(10):e3660-71. PubMed ID: 32738042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in body mass index during gonadotropin-releasing hormone agonist treatment for central precocious puberty and early puberty.
    Lee HS; Yoon JS; Roh JK; Hwang JS
    Endocrine; 2016 Nov; 54(2):497-503. PubMed ID: 27444748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anthropometric, metabolic, and reproductive outcomes of patients with central precocious puberty treated with leuprorelin acetate 3-month depot (11.25 mg).
    Ramos CO; Canton APM; Seraphim CE; Faria AG; Tinano FR; Mendonca BB; Latronico AC; Brito VN
    J Pediatr Endocrinol Metab; 2021 Nov; 34(11):1371-1377. PubMed ID: 34298591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant adverse reactions to long-acting gonadotropin-releasing hormone agonists for the treatment of central precocious puberty and early onset puberty.
    Lee JW; Kim HJ; Choe YM; Kang HS; Kim SK; Jun YH; Lee JE
    Ann Pediatr Endocrinol Metab; 2014 Sep; 19(3):135-40. PubMed ID: 25346917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of gonadotropin secretion by a long-acting gonadotropin-releasing hormone analog (leuprolide acetate, Lupron Depot) in children with precocious puberty.
    Kappy M; Stuart T; Perelman A; Clemons R
    J Clin Endocrinol Metab; 1989 Nov; 69(5):1087-9. PubMed ID: 2507570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with Depot Leuprolide Acetate in Girls with Idiopathic Precocious Puberty: What Parameter should be Used in Deciding on the Initial Dose?
    Vurallı D; Alikaşifoğlu A; İyigün İ; Canoruç D; Ozon A; Gönç N; Kandemir N
    J Clin Res Pediatr Endocrinol; 2020 Mar; 12(1):37-44. PubMed ID: 31347350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls.
    Brito VN; Latronico AC; Arnhold IJ; Mendonca BB
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4338-42. PubMed ID: 15356030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leuprolide Acetate and QTc Interval in Gender-Diverse Youth.
    Waldner RC; Doulla M; Atallah J; Rathwell S; Grimbly C
    Transgend Health; 2023 Feb; 8(1):84-88. PubMed ID: 36895314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty.
    Lee PA; Klein K; Mauras N; Lev-Vaisler T; Bacher P
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3153-9. PubMed ID: 24926950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Auxological and biochemical evaluation of pubertal suppression with the GnRH agonist leuprolide acetate in early and precocious puberty.
    Mul D; de Muinck Keizer-Schrama SM; Oostdijk W; Drop SL
    Horm Res; 1999 Dec; 51(6):270-6. PubMed ID: 10640887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of depot leuprolide acetate dose-adequacy for central precocious puberty.
    Cook JS; Doty KL; Conn PM; Hansen JR
    J Clin Endocrinol Metab; 1992 May; 74(5):1206-9. PubMed ID: 1569169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudotumor cerebri in patient on leuprolide acetate for central precocious puberty.
    Omar AA; Nyaga G; Mungai LNW
    Int J Pediatr Endocrinol; 2020 Dec; 2020(1):22. PubMed ID: 33292495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs.
    Lanes R; Soros A; Jakubowicz S
    J Pediatr Endocrinol Metab; 2004 May; 17(5):759-66. PubMed ID: 15237711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of bone maturation, growth rate and adult height in children with central precocious puberty treated with depot leuprolide acetate.
    Klein KO; Dragnic S; Soliman AM; Bacher P
    J Pediatr Endocrinol Metab; 2018 Jun; 31(6):655-663. PubMed ID: 29750651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal assessment of auxological parameters, adult height outcome and its determinants in leuprolide-treated Indian girls with idiopathic central precocious puberty.
    Mondkar S; Khadilkar V; Yewale S; Dange N; More C; Khadilkar A
    J Pediatr Endocrinol Metab; 2024 Jan; 37(1):62-68. PubMed ID: 38008794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.